Molecular and Pathological Profiling of Corresponding Treatment-Naïve and Neoadjuvant Pazopanib-Treated High-Risk Soft Tissue Sarcoma Samples of the GISG-04/NOPASS Study.
BRAF V600E
CDK4
MAP2K1 E203K
NGS
STS
next generation sequencing
pazopanib
soft tissue sarcoma
Journal
Biology
ISSN: 2079-7737
Titre abrégé: Biology (Basel)
Pays: Switzerland
ID NLM: 101587988
Informations de publication
Date de publication:
09 Jul 2021
09 Jul 2021
Historique:
received:
15
06
2021
accepted:
07
07
2021
entrez:
6
8
2021
pubmed:
7
8
2021
medline:
7
8
2021
Statut:
epublish
Résumé
In the framework of the German Interdisciplinary Sarcoma Group GISG-04/NOPASS trial, we evaluated soft tissue sarcoma samples taken before and after neoadjuvant pazopanib therapy using histopathology and next generation sequencing (NGS) to find potential predictive biomarkers. We also aimed to improve the genetically based sarcoma classification and to elucidate additional potentially druggable mutations. In total, 30 tumor samples from 18 patients consisting of 12 pre-therapeutic biopsies and 18 resection specimens following neoadjuvant pazopanib therapy were available for analyses. NGS was performed with the Oncomine Focus Assay (Ion Torrent) covering 0.03 Mb of DNA and enabled the detection of genetic variants in 52 cancer-relevant genes. Pathological analysis showed significant regression (≥50%) after pazopanib treatment in only one undifferentiated (pleomorphic) sarcoma. NGS analyses revealed a very high frequency of
Identifiants
pubmed: 34356494
pii: biology10070639
doi: 10.3390/biology10070639
pmc: PMC8301157
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Novartis
Organisme : GlaxoSmithKline
Organisme : Medical Faculty of the Martin-Luther-University Halle-Wittenberg
ID : Advanced Clinician Scientist Program
Références
Cancer. 2017 Dec 1;123(23):4640-4647
pubmed: 28832986
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Int J Mol Sci. 2020 Mar 21;21(6):
pubmed: 32245216
Cureus. 2015 Dec 28;7(12):e439
pubmed: 26858920
Jpn J Clin Oncol. 2019 Feb 1;49(2):103-107
pubmed: 30423153
Nat Genet. 2012 May;44(5):570-4
pubmed: 22484628
Neoplasia. 2015 Apr;17(4):385-99
pubmed: 25925381
Ann Oncol. 2014 Mar;25(3):719-724
pubmed: 24504442
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Lancet. 2012 May 19;379(9829):1879-86
pubmed: 22595799
J Surg Oncol. 2011 Apr;103(5):371-9
pubmed: 21400518
Pathobiology. 2017;84(6):323-338
pubmed: 28817827
Hum Pathol. 2014 Aug;45(8):1563-71
pubmed: 24908143
Brief Bioinform. 2013 Mar;14(2):178-92
pubmed: 22517427
N Engl J Med. 2018 May 17;378(20):1945-1947
pubmed: 29768143
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
BMJ Open. 2016 Jan 06;6(1):e009558
pubmed: 26739732
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Ann Oncol. 2016 Mar;27(3):539-43
pubmed: 26646755
Cell. 2017 Nov 2;171(4):950-965.e28
pubmed: 29100075
Cancers (Basel). 2019 Jun 08;11(6):
pubmed: 31181713
Clin Orthop Relat Res. 2020 Nov;478(11):2461-2476
pubmed: 32567826
Ann Surg Oncol. 2019 May;26(5):1332-1339
pubmed: 30843160
N Engl J Med. 2015 Aug 20;373(8):726-36
pubmed: 26287849
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv51-iv67
pubmed: 29846498
Oncologist. 2018 Feb;23(2):234-242
pubmed: 28860410
Acta Oncol. 2017 Jan;56(1):88-92
pubmed: 27838944
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Nucleic Acids Res. 2014 Jan;42(Database issue):D980-5
pubmed: 24234437